Tamara T. Koopmann

Tamara T. Koopmann

Auto-generated profile, based on publicly available information

Tamara T. Koopmann

Department of Clinical Genetics Leiden University Medical Center Leiden The Netherlands

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 June 2022 in Genome Medicine
Verified
Journal Article
Open access
PDF file
MCMargot A. Cousin
Margot A. Cousin
EVEmma L. Veale
Emma L. Veale
NDNikita R. Dsouza
Nikita R. Dsouza
STSwarnendu Tripathi
Swarnendu Tripathi
RHRobyn G. Holden
Robyn G. Holden
EKEric W. Klee
Eric W. Klee
Background: Genomics enables individualized diagnosis and treatment, but large challenges remain to functionally interpret rare variants. To date, only one causative variant has been described for KCNK9 imprinting syndrome (KIS). The genotypic and phenotypic spectrum of KIS has yet to be described and the precise mechanism of disease fully understood. Methods: This study discovers mechanisms underlying KCNK9 imprinting syndrome (KIS) by describing 15 novel KCNK9 alterations from 47 KIS-affected individuals. We use clinical genetics and computer-assisted facial phenotyping to describe the phenotypic spectrum of KIS. We then interrogate the functional effects of the variants in the encoded TASK3 channel using sequence-based analysis, 3D molecular mechanic and dynamic protein modeling, and in vitro electrophysiological and functional methodologies. Results: We describe the broader genetic and phenotypic variability for KIS in a cohort of individuals identifying an additional mutational hotspot at p.Arg131 and demonstrating the common features of this neurodevelopmental disorder to include motor and speech delay, intellectual disability, early feeding difficulties, muscular hypotonia, behavioral abnormalities, and dysmorphic features. The computational protein modeling and in vitro electrophysiological studies discover variability of the impact of KCNK9 variants on TASK3 channel function identifying variants causing gain and others causing loss of conductance. The most consistent functional impact of KCNK9 genetic variants, however, was altered channel regulation. Conclusions: This study extends our understanding of KIS mechanisms demonstrating its complex etiology including gain and loss of channel function and consistent loss of channel regulation. These data are rapidly applicable to diagnostic strategies, as KIS is not identifiable from clinical features alone and thus should be molecularly diagnosed. Furthermore, our data suggests unique therapeutic strategies may be needed to address the specific functional consequences of KCNK9 variation on channel function and regulation.

29 February 2024 in Clinical Genetics
Verified
Journal Article
Open access
CPCaroline Pham
Caroline Pham
TKTamara T. Koopmann
Tamara T. Koopmann
JVJeffrey M. Vinocur
Jeffrey M. Vinocur
NBNico Blom
Nico Blom
VSVivian Nogueira Silbiger
Vivian Nogueira Silbiger
ELElisabeth Lodder
Elisabeth Lodder
Genetic missense variants in TNNI3K, encoding troponin‐I interacting kinase, have been associated with dilated cardiomyopathy (DCM) and observed in families with supraventricular tachycardias (SVT). Previously, a family harboring the TNNI3K‐c.1615A > G (p.Thr539Ala) variant presented with congenital junctional ectopic tachycardia (CJET), an arrhythmia that arises from the atrioventricular (AV) node and His bundle. However, this was a relatively small four‐generational family with limited genetic testing (N = 3). We here describe a multigenerational family with CJET harboring a novel ultra‐rare TNNI3K variant: TNNI3K‐c.1729C > T (p.Leu577Phe). Of all 18 variant carriers, 13 individuals presented with CJET, resulting in a genetic penetrance of 72%. In addition, CJET is reported in another small family harboring TNNI3K‐c.2225C > T (p.Pro742Leu). Similar to the previously published CJET family, both TNNI3K variants demonstrate a substantial reduction of kinase activity. Our study contributes novel evidence supporting the involvement of TNNI3K genetic variants as significant contributors to CJET, shedding light on potential mechanisms underlying this cardiac arrhythmia.

1 November 2026 in medRxiv
Verified
Preprint
Open access
PDF file
CSCoralea Stephanou
Coralea Stephanou
IFIrene Fylaktou
Irene Fylaktou
HHHashim Halim-Fikri
Hashim Halim-Fikri
TKTamara T Koopmann
Tamara T Koopmann
LNLandry E Nfonsam
Landry E Nfonsam
CPClinGen Hemoglobinopathy Variant Curation Expert Panel
ClinGen Hemoglobinopathy Variant Curation Expert Panel
Background: The ClinGen Hemoglobinopathy Variant Curation Expert Panel (VCEP) was established in 2019 to develop disease-specific adaptations of the American College of Medical Genetics and Genomics/Association for Molecular Pathology (ACMG/AMP) sequence variant interpretation framework for hemoglobinopathies. This study describes the development, validation, and ClinGen approval of the first disease-specific ACMG/AMP specifications for autosomal recessive thalassemia related to HBB and HBA2, providing a standardized framework for globin gene variant interpretation. Methods: Disease-specific ACMG/AMP rule specifications were developed in accordance with ClinGen procedures and Variant Classification Working Group recommendations and evaluated through pilot curation of representative HBB and HBA2 variants using the ClinGen Variant Curation Interface (VCI), with independent biocurator assessment, expert review, and consensus approval. Results: A total of 34 disease-specific evidence specifications were developed across the two gene-disease pairs, encompassing 22 ACMG/AMP evidence criteria and one modification to the ACMG/AMP evidence-combining rules. Pilot application to 33 representative variants (20 HBB, 13 HBA2) demonstrated high concordance with established pathogenic and benign classifications while providing a standardized framework for resolving variants with conflicting or limited evidence. Following pilot validation, the specifications received ClinGen approval, and all curated variants with supporting evidence were disseminated through the ClinGen Evidence Repository (ERepo) and ClinVar. Conclusions: The ClinGen Hemoglobinopathy VCEP specifications provide the first ClinGen-approved disease-specific ACMG/AMP rule specifications for HBB and HBA2 variants related to thalassemia. These specifications establish a robust and transparent framework for harmonized globin variant interpretation and provide a foundation for sustained expert curation, continued refinement through emerging evidence, and expansion to additional hemoglobinopathy gene-disease pairs.